Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;8(1):e002308.
doi: 10.1136/rmdopen-2022-002308.

Very low rate of humoral response after a third COVID-19 vaccine dose in patients with autoimmune diseases treated with rituximab and non-responders to two doses

Samuel Bitoun  1 , Jérôme Avouac  2 , Julien Henry  3 , Roba Ghossan  2 , Omar Al Tabaa  2 , Rakiba Belkhir  3 , Gaetane Nocturne  3 , Alice Andrée Mariaggi  4 , Flore Rozenberg  4 , Christelle Vauloup-Fellous  5 , Xavier Mariette  3 , Raphaèle Seror  3
Affiliations

Very low rate of humoral response after a third COVID-19 vaccine dose in patients with autoimmune diseases treated with rituximab and non-responders to two doses

Samuel Bitoun et al. RMD Open. 2022 May.
No abstract available

Keywords: Arthritis, Rheumatoid; Autoimmune Diseases; COVID-19; Rituximab; Vaccination.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

References

    1. Bitoun S, Henry J, Desjardins D, et al. . Rituximab impairs B cell response but not T cell response to COVID-19 vaccine in autoimmune diseases. Arthritis Rheumatol 2021. 10.1002/art.42058. [Epub ahead of print: 28 Dec 2021]. - DOI - PMC - PubMed
    1. Avouac J, Miceli-Richard C, Combier A, et al. . Risk factors of impaired humoral response to COVID-19 vaccination in rituximab treated patients. Rheumatology 2021:keab815. 10.1093/rheumatology/keab815 - DOI - PMC - PubMed
    1. Felten R, Gallais F, Schleiss C. Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab. Lancet Rheumatol. - PMC - PubMed
    1. Schmiedeberg K, Vuilleumier N, Pagano S, et al. . Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses. Lancet Rheumatol 2022;4:e11–13. 10.1016/S2665-9913(21)00328-3 - DOI - PMC - PubMed
    1. Kamar N, Abravanel F, Marion O, et al. . Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients. N Engl J Med 2021;385:661–2. 10.1056/NEJMc2108861 - DOI - PMC - PubMed